Patents by Inventor William I. Cox
William I. Cox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8921534Abstract: The invention relates to reagents and methods for enhancing an immune response using CD36 binding region/antigen hybrid polypeptides or polynucleotides encoding the hybrid polypeptides.Type: GrantFiled: December 12, 2002Date of Patent: December 30, 2014Inventors: William I. Cox, Jeannine P. Alexander, Scott Goebel
-
Publication number: 20080188640Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro) (IIIB), gp120(MN) (+transmembrane), nef (BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro) (IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: ApplicationFiled: August 8, 2007Publication date: August 7, 2008Inventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Publication number: 20040241652Abstract: The invention relates to reagents and methods for enhancing an immune response using CD36 binding region/antigen hybrid polypeptides or polynucleotides encoding the hybrid polypeptides.Type: ApplicationFiled: December 12, 2002Publication date: December 2, 2004Applicant: Aventis Pasteur LimitedInventors: William I. Cox, Jeannine P. Alexander, Scott Goebel
-
Patent number: 6780407Abstract: Attenutated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wiltype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.Type: GrantFiled: September 15, 2000Date of Patent: August 24, 2004Assignee: Aventis PasteurInventors: Enzo Paoletti, James Tartaglia, William I. Cox
-
Publication number: 20030223987Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: ApplicationFiled: May 20, 2003Publication date: December 4, 2003Inventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Publication number: 20030198623Abstract: Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFNg; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.Type: ApplicationFiled: October 9, 2002Publication date: October 23, 2003Inventors: Enzo Paoletti, James Tartaglia, William I. Cox
-
Patent number: 6632438Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: July 26, 2001Date of Patent: October 14, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffmann
-
Patent number: 6596279Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: GrantFiled: August 14, 1998Date of Patent: July 22, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Publication number: 20030064077Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: ApplicationFiled: July 26, 2001Publication date: April 3, 2003Applicant: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffman
-
Patent number: 6541250Abstract: The present invention comprises a novel immortal non-adherent human melanocyte cell line, designated WC-1 14.07. This cell line is stable and MHC class I negative. This continuous melanocyte cell line can be used as a source of melanin and hgp100. The Class I MHC-negative nature of this cell line allows it to be used as a target for transfection with MHC class I genes, providing a novel source of hgp100 in a pre-determined MHC context. The cell line can thus be used in a variety of ways, directly or indirectly, in the development and manufacture of vaccines for melanoma.Type: GrantFiled: April 18, 2001Date of Patent: April 1, 2003Assignee: Aventis Pasteur LimitedInventors: Jeannine Alexander, William I. Cox
-
Patent number: 6537594Abstract: Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.Type: GrantFiled: March 24, 2000Date of Patent: March 25, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox
-
Publication number: 20020006662Abstract: The present invention comprises a novel immortal non-adherent human melanocyte cell line, designated WC-1 14.07. This cell line is stable and MHC class I negative. This continuous melanocyte cell line can be used as a source of melanin and hgp100. The Class I MHC-negative nature of this cell line allows it to be used as a target for transfection with MHC class I genes, providing a novel source of hgp100 in a pre-determined MHC context. The cell line can thus be used in a variety of ways, directly or indirectly, in the development and manufacture of vaccines for melanoma.Type: ApplicationFiled: April 18, 2001Publication date: January 17, 2002Inventors: Jeannine Alexander, William I. Cox
-
Patent number: 6267965Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: May 26, 1998Date of Patent: July 31, 2001Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffman
-
Patent number: 6265189Abstract: Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.Type: GrantFiled: June 2, 1995Date of Patent: July 24, 2001Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox
-
Patent number: 6130066Abstract: Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector, or at different loci.Type: GrantFiled: May 15, 1998Date of Patent: October 10, 2000Assignee: Virogenetics CorporationInventors: James Tartaglia, William I. Cox, Russell Robert Gettig, Hector Martinez, Enzo Paoletti, Steven E. Pincus
-
Patent number: 6017537Abstract: The present invention relates to immunological adjuvants comprised of the N-formyl methionyl peptide fMLP. FMLP, when used as an adjuvant in accordance with the present invention, provides for an immune response to suboptimal doses of recombinant antigens.Type: GrantFiled: December 18, 1998Date of Patent: January 25, 2000Assignee: Connaught Laboratories, Inc.Inventors: Jeannine Alexander, William I. Cox
-
Patent number: 6004777Abstract: Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector or at different loci. The second nucleic acid molecule can encode encode one translation factor or more than one translation factor.Type: GrantFiled: March 12, 1997Date of Patent: December 21, 1999Assignees: Virogenetics Corporation, Arizona State UniversityInventors: James Tartaglia, Bertram L. Jacobs, Scott J. Goebel, William I. Cox, Russell Robert Gettig, Steven E. Pincus, Enzo Paoletti
-
Patent number: 5997878Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: June 5, 1996Date of Patent: December 7, 1999Assignee: Connaught LaboratoriesInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth B. Kauffman
-
Patent number: 5990091Abstract: Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector, or at different loci.Type: GrantFiled: March 12, 1997Date of Patent: November 23, 1999Assignee: Virogenetics CorporationInventors: James Tartaglia, William I. Cox, Russell Robert Gettig, Hector Martinez, Enzo Paoletti, Steven E. Pincus
-
Patent number: 5863542Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: GrantFiled: April 5, 1995Date of Patent: January 26, 1999Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox